Rapamycin induces growth retardation by disrupting angiogenesis in the growth plate

Kidney International

Volumn 78, Issue 6, 2010, Pages 561-568

  Álvarez García, Óscar ^a   García López, Enrique ^b   Loredo, Vanessa ^a   Gil Pẽa, Helena ^a   Rodríguez Suárez, Julián ^a   Ordó̃ez, Flor Å ^a   Carbajo Pérez, Eduardo ^c   Santos, Fernando ^a,c  

^a HOSPITAL UNIVERSITARIO CENTRAL DE ASTURIAS   (Spain)

^b HOSPITAL ÁLVAREZ BUYLLA   (Spain)

^c UNIVERSITY OF OVIEDO   (Spain)

Author keywords

children; pediatric kidney transplantation; transplantation; vascular endothelial growth factor

Indexed keywords

BROXURIDINE; CALCEIN; GROWTH HORMONE; MESSENGER RNA; RAPAMYCIN; SOMATOMEDIN C; VASCULOTROPIN;

ANGIOGENESIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BODY WEIGHT; CARTILAGE CELL; CONTROLLED STUDY; DRUG MECHANISM; FOOD INTAKE; GROWTH PLATE; GROWTH RETARDATION; KIDNEY TRANSPLANTATION; MALE; NONHUMAN; OSTEOCLAST; PRIORITY JOURNAL; RAT;

EID: 77956226075     PISSN: 00852538     EISSN: 15231755     Source Type: Journal    
DOI: 10.1038/ki.2010.173     Document Type: Article

References (34)

1. Chueh SC, Kahan BD. Clinical application of sirolimus in renal transplantation: an update. Transpl Int 2005; 18: 261-277.
2. Flechner SM, Goldfarb D, Modlin C et al. Kidney transplantation without calcineurin inhibitor drugs: a prospective, randomized trial of sirolimus versus cyclosporine. Transplantation 2002; 74: 1070-1076.
3. Morales JM, Campistol JM, Kreis H et al. Sirolimus-based therapy with or without cyclosporine: long-term follow-up in renal transplant patients. Transplant proc 2005; 37: 693-696.
4. Kahan BD, Knight R, Schoenberg L et al. Ten years of sirolimus therapy for human renal transplantation: the University of Texas at Houston experience. Transplant Proc 2003; 35: 25s-34s.
5. Mathew T, Kreis H, Friend P. Two-year incidence of malignancy in sirolimus-treated renal transplant recipients: results from five multicenter studies. Clin Transplant 2004; 18: 446-449.
6. Stallone G, Schena A, Infante B. Sirolimus for Kaposi's sarcoma in renal-transplant recipients. N Engl J Med 2005; 352: 1317-1323.
7. Motzer RJ, Escudier B, Oudard S, et al., for the RECORD-1 Study Group. Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. Lancet 2008; 372: 449-456.
8. Bissler JJ, McCormack FX, Young LR et al. Sirolimus for angiomyolipoma in tuberous sclerosis complex or lymphangioleiomyomatosis. N Engl J Med 2008; 358: 140-151.
9. Hay N, Sonenberg N. Upstream and downstream of mTOR. Genes Dev 2004; 18: 1926-1945.
10. Guba M, von Breitenbuch P, Steinbauer M et al. Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: involvement of vascular endothelial growth factor. Nat Med 2002; 8: 128-135.
11. Cravedi P, Ruggenenti P, Remuzzi G. Sirolimus to replace calcineurin inhibitors? Too early yet. Lancet 2009; 373: 1235-1236.
12. Ibáñez JP, Monteverde ML, Goldberg J et al. Sirolimus in pediatric renal transplantation. Transplant Proc 2005; 37: 682-684.
13. Alvarez-Garcia O, Carbajo-Pérez E, Garcia E et al. Rapamycin retards growth and causes marked alterations in the growth plate of young rats. Pediatr Nephrol 2007; 22: 954-961.
14. Sanchez CP, He YZ. Bone growth during rapamycin therapy in young rats. BMC Pediatr 2009; 9: 3.
15. Phornphutkul C, Lee M, Voigt C et al. The effect of rapamycin on bone growth in rabbits. J Orthop Res 2009; 27: 1157-1161.
16. Hall MN. mTOR-what does it do? Transplant Proc 2008; 40: 5s-58s.
17. Rommel C, Bodine SC, Clarke BA et al. Mediation of IGF-1-induced skeletal myotube hypertrophy by PI(3)K/Akt/mTOR and PI(3)K/Akt/GSK3 pathways. Nat Cell Biol 2001; 3: 1009-1013.
18. Starkman BG, Cravero JD, Delcarlo M et al. IGF-I stimulation of proteoglycan synthesis by chondrocytes requires activation of the PI 3-kinase pathway but not ERK MAPK. Biochem J 2005; 389: 723-729.
19. Coolican SA, Samuel DS, Ewton DZ et al. The mitogenic and myogenic actions of insulin-like growth factors utilize distinct signaling pathways. J Biol Chem 1997; 272: 6653-6662.
20. van der Eerden BC, Karperien M, Wit JM. Systemic and local regulation of the growth plate. Endocr Rev 2003; 24: 782-801.
21. Gerber HP, Vu TH, Ryan AM et al. VEGF couples hypertrophic cartilage remodeling, ossification and angiogenesis during endochondral bone formation. Nat Med 1999; 5: 623-628.
22. Del Bufalo D, Ciuffreda L, Trisciuoglio D et al. Antiangiogenic potential of the mammalian target of rapamycin inhibitor temsirolimus. Cancer Res 2006; 66: 5549-5554.
23. El-Hashemite N, Walker V, Zhang H et al. Loss of Tsc1 or Tsc2 induces vascular endothelial growth factor production through mammalian target of rapamycin. Cancer Res 2003; 63: 5173-5177.
24. Luan FL, Ding R, Sharma VK et al. Rapamycin is an effective inhibitor of human renal cancer metastasis. Kidney Int 2003; 63: 917-926.
25. Diekmann F, Rovira J, Carreras J et al. Mammalian target of rapamycin inhibition halts the progression of proteinuria in a rat model of reduced renal mass. J Am Soc Nephrol 2007; 18: 2653-2660.
26. Pugh CW, Ratcliffe PJ. Regulation of angiogenesis by hypoxia: role of the HIF system. Nat Med 2003; 9: 677-684.
27. Le Roith D, Bondy C, Yakar S et al. The somatomedin hypothesis: 2001. Endocr Rev 2001; 22: 53-74.
28. Kiepe D, Ciarmatori S, Hoeflich A et al. Insulin-like growth factor (IGF)-I stimulates cell proliferation and induces IGF binding protein (IGFB)-3 and IGFBP-5 gene expression in cultured growth plate chondrocytes via distinct signaling pathways. Endocrinology 2005; 146: 3096-3104.
29. Bohensky J, Terkhorn SP, Freeman TA et al. Regulation of autophagy in human and murine cartilage: hypoxia-inducible factor 2 suppresses chondrocyte autophagy. Arthritis Rheum 2009; 60: 1406-1415.
30. Srinivas V, Shapiro IM. Chondrocytes embedded in the epiphyseal growth plates of long bones undergo autophagy prior to the induction of osteogenesis. Autophagy 2006; 2: 215-216.
31. Ma J, Meng Y, Kwiatkowski DJ et al. Mammalian target of rapamycin regulates murine and human cell differentiation through STAT3/p63/Jagged/Notch cascade. J Clin Invest 2010; 120: 103-114.
32. Molinos I, Santos F, Carbajo-Perez E et al. Catch-up growth follows an abnormal pattern in experimental renal insufficiency and growth hormone treatment normalizes it. Kidney Int 2006; 70: 1955-1961.
33. Gil-Peña H, Garcia-Lopez E, Alvarez-Garcia O et al. Alterations of growth plate and abnormal insulin-like growth factor I metabolism in growth-retarded hypokalemic rats: effect of growth hormone treatment. Am J Physiol Renal Physiol 2009; 297: 639-645.
34. Chomczynski P, Sacchi N. The single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction: twenty-something years on. Nat Protoc 2006; 1: 581-585.